Uroguanylin analog (DNIB Unwind/Synergy)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameUroguanylin analog (DNIB Unwind/Synergy)
Drug Alias Nameguanylate cyclase-C agonists (BIND/Synergy)Uroguanylin analog (BIND/Synergy)GC-C agonist (BIND/Synergy)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionNatriuretic peptide receptor 3 agonists
TargetsNatriuretic peptide receptor 3
Therapy Area/IndicationsGastrointestinal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDNIB Unwind Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDNIB Unwind IncPfizer IncSynergy Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsGastrointestinal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A